ARCTURUS THERAPEUTICS HOLDINGS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.23M, a 31.76% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.33M, a 35.08% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.73M, a 39.65% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.20M, a 34.21% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $25.41M, a 33.12% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $37.99M, a 9.64% increase from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $34.65M, a 13.19% increase from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $30.61M, a 5.87% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.23M 10-Q · filed 2026-08-06 | $8.56M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $4.33M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $25.41M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $5.73M 10-Q · filed 2025-11-12 | $11.93M derived: sum of 2 quarters · filed 2026-08-06 | $18.59M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $6.20M 10-Q · filed 2026-08-06 | $12.86M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $6.66M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $37.99M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $9.49M 10-Q · filed 2025-11-12 | $18.92M derived: sum of 2 quarters · filed 2025-11-12 | $29.00M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $9.42M 10-Q · filed 2025-11-12 | $19.51M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $10.09M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $34.65M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $9.27M 10-Q · filed 2024-11-07 | $17.65M derived: sum of 2 quarters · filed 2024-11-07 | $25.83M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $8.38M 10-Q · filed 2024-11-07 | $16.57M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $8.18M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $30.61M 10-K · filed 2025-03-06 | |||
| 2022-09-30 | $9.44M 10-Q · filed 2023-11-14 | $16.71M derived: sum of 2 quarters · filed 2023-11-14 | $24.08M derived: sum of 3 quarters · filed 2023-11-14 | $31.60M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $7.27M 10-Q · filed 2023-11-14 | $14.64M 10-Q · filed 2022-08-09 | $22.16M derived: sum of 3 quarters · filed 2024-03-14 | $29.03M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $7.37M 10-Q · filed 2023-11-14 | $14.89M derived: sum of 2 quarters · filed 2024-03-14 | $21.76M derived: sum of 3 quarters · filed 2024-03-14 | $29.30M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $14.39M derived: sum of 2 quarters · filed 2024-03-14 | $21.93M derived: sum of 3 quarters · filed 2024-03-14 | $28.91M 10-K · filed 2024-03-14 |
| 2021-09-30 | $6.87M 10-Q · filed 2022-11-09 | $14.41M derived: sum of 2 quarters · filed 2022-11-09 | $21.40M 10-Q · filed 2021-11-09 | $24.22M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $7.54M 10-Q · filed 2022-11-09 | $14.53M 10-Q · filed 2022-08-09 | $17.35M derived: sum of 3 quarters · filed 2022-11-09 | $19.34M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-03-31 | $6.99M 10-Q · filed 2022-11-09 | $9.81M derived: sum of 2 quarters · filed 2022-11-09 | $11.80M derived: sum of 3 quarters · filed 2022-11-09 | $12.90M derived: sum of 4 quarters · filed 2022-11-09 |
| 2020-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.81M derived: sum of 2 quarters · filed 2022-03-01 | $5.92M derived: sum of 3 quarters · filed 2022-03-01 | $6.76M 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.99M 10-Q · filed 2021-11-09 | $3.09M derived: sum of 2 quarters · filed 2021-11-09 | $3.94M 10-Q · filed 2021-11-09 | $4.74M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $1.10M 10-Q · filed 2021-08-10 | $1.95M 10-Q · filed 2021-08-10 | $2.75M derived: sum of 3 quarters · filed 2022-03-01 | $3.13M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $849.00K 10-Q · filed 2021-05-10 | $1.65M derived: sum of 2 quarters · filed 2022-03-01 | $2.03M derived: sum of 3 quarters · filed 2022-03-01 | $2.43M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $797.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.18M derived: sum of 2 quarters · filed 2022-03-01 | $1.58M derived: sum of 3 quarters · filed 2022-03-01 | $1.98M 10-K · filed 2022-03-01 |
| 2019-09-30 | $383.00K 10-Q · filed 2020-11-09 | $786.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.19M 10-Q · filed 2020-11-09 | $1.69M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $403.00K 10-Q · filed 2020-08-10 | $802.00K 10-Q · filed 2020-08-10 | $1.31M derived: sum of 3 quarters · filed 2021-03-01 | $1.90M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $399.00K 10-Q · filed 2020-05-08 | $905.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.49M derived: sum of 3 quarters · filed 2021-03-01 | $1.63M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $506.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.09M derived: sum of 2 quarters · filed 2021-03-01 | $1.23M derived: sum of 3 quarters · filed 2021-03-01 | $1.26M 10-K · filed 2021-03-01 |
| 2018-09-30 | $587.00K 10-Q · filed 2019-11-08 | $727.00K derived: sum of 2 quarters · filed 2019-11-08 | $753.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $140.00K 10-Q · filed 2019-08-14 | $166.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |